The global omega-3 prescription drugs market is undergoing a period of robust expansion, projected to grow from USD 1.45 billion in 2024 to USD 2.46 billion by 2032, exhibiting a healthy CAGR of 6.85% from 2025 to 2032. This surge is primarily propelled by increasing global cardiovascular disease prevalence, heightened clinical trust in evidence-based EPA/DHA therapies, and strategic pharmaceutical developments worldwide.
Omega-3 prescription drugs, particularly formulations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are widely prescribed to reduce triglyceride levels and mitigate cardiovascular risks. Growing clinical evidence, ongoing trials, and endorsements from regulatory authorities have significantly improved market acceptance and patient compliance.
Get Insights into Market Movements: Request a Sample Report! https://www.snsinsider.com/sample-request/7044
Market Trends & Growth Catalysts
Cardiovascular Disease as a Global Health Crisis
Cardiovascular disease (CVD) remains the leading cause of death globally, claiming an estimated 18 million lives annually. According to the CDC, in the U.S. alone, one person dies every 36 seconds from cardiovascular disease, reinforcing the urgent need for preventive therapies such as omega-3 prescription medications.
Physician Recommendations & Clinical Trials
Physicians are increasingly recommending omega-3 prescription drugs as part of integrated lipid-lowering therapy, based on clinical trials studies such as REDUCE-IT, which underscore the cardiovascular benefits of EPA-rich formulations. This has led to significant prescription uptakes across developed markets.
Macro-Economic Enablers
- Rising healthcare expenditure in emerging economies
- Aging population and increased life expectancy
- Growing health awareness and diagnostics for lipid abnormalities
- Regulatory support for fast-tracking approvals and generic formulations
Recent Industry Milestones
- Hikma Pharmaceuticals launched generic Icosapent Ethyl Capsules in the U.S. in March 2023, increasing affordability and access.
- China’s NMPA granted approval for Vascepa (Icosapent Ethyl) in February 2023, marking a crucial step toward Asia-Pacific market penetration.
Regional Insights
North America: Market Leader with 43% Share in 2024
North America held the lion’s share of the global market in 2024, led by the U.S., which alone accounted for USD 0.49 billion in sales. This dominance stems from:
- High prevalence of cardiovascular and obesity-related conditions
- Strong insurance coverage for prescription lipid therapies
- Widespread physician adoption of omega-3 prescription guidelines
- Robust presence of top-tier pharmaceutical companies
Canada and Mexico are also contributing to market expansion, supported by growing healthcare investments and patient awareness initiatives.
Europe: Second-Largest Market with Strong Regulatory and Clinical Backbone
Europe followed North America, with significant market contributions from Germany, France, the UK, and Italy. Key factors include:
- Institutional focus on cardiovascular prevention
- Regulatory endorsement of omega-3 therapies
- Widespread access to healthcare services
Germany, in particular, stands out due to its well-established healthcare system and favorable reimbursement policies for omega-3 pharmaceuticals, accelerating both patient access and physician trust.
Asia-Pacific: Fastest-Growing Market with 7.41% CAGR Forecast
Asia-Pacific is expected to witness the fastest growth through 2032, driven by:
- Rapidly aging population
- Escalating burden of chronic diseases (cardiovascular disease, diabetes, hypertension)
- Government initiatives to expand pharmaceutical reach and healthcare accessibility
Countries like China, India, and Japan are leading the charge. China’s recent regulatory nod to Vascepa is a pivotal development signaling future demand surge. Rising income levels and urban health awareness also contribute to this expansion.
Key Players in the Market
Prominent players contributing to the growth and innovation in this space include:
- Sun Pharmaceutical Industries Ltd.
- Amarin Pharmaceuticals Ireland Limited
- PuraCap Pharmaceutical LLC
- Wilshire Pharmaceuticals, INC.
- Woodward Pharma Services LLC
- CSPC Pharmaceutical Group Limited
- Sofgen
- GLW Pharma GMBH
- ChartwellPharma
- Amneal Pharmaceuticals LLC
- Mankind Pharma
- Others
These companies are actively involved in launching new formulations, expanding into untapped markets, and engaging in collaborative research to improve efficacy and reduce side effects of omega-3 prescription drugs market.
Recent Developments
- Launching generic Icosapent Ethyl Capsules in the U.S. in March 2023, Hikma Pharmaceuticals increases access to EPA-based prescription omega-3 fatty acids for hypertriglyceridemia treatment and cardiovascular risk reduction.
- A major turning point for EPA/DHA medications in the Asia-Pacific area, China’s NMPA authorized Vascepa (Icosapent Ethyl) in February 2023, therefore boosting Omega 3 Prescription Drug Trends.
- Aiming at people with excessive triglycerides at cardiovascular risk, Portugal approved national reimbursement for Amarin’s VAZKEPA in July 2024. Supporting Amarin’s aim to increase access and fight cardiovascular disease, which causes 29% of annual deaths in Portugal, this represents its eighth reimbursement in Europe.
Strategic Growth with Comprehensive Insights Request Checkout Now! https://www.snsinsider.com/checkout/7044
Key Market Segmentation
By Drug
- Vascepa
- Lovaza
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Application
- Cardiovascular Disease
- Others (including hypertriglyceridemia and metabolic syndromes)
As the world increasingly shifts towards preventive healthcare and personalized medicine, omega-3 prescription drugs are becoming a cornerstone in lipid management and cardiovascular disease prevention. Strategic partnerships, regulatory support, and ongoing R&D will further fuel market momentum through 2032.
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Mail us: [email protected]
